KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $196.9 million.

  • Sarepta Therapeutics' Income from Continuing Operations rose 294857.59% to $196.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $395.8 million, marking a year-over-year increase of 73977.76%. This contributed to the annual value of $235.0 million for FY2024, which is 14382.98% up from last year.
  • Sarepta Therapeutics' Income from Continuing Operations amounted to $196.9 million in Q2 2025, which was up 294857.59% from $158.8 million recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' Income from Continuing Operations registered a high of $196.9 million during Q2 2025, and its lowest value of -$516.8 million during Q1 2023.
  • Over the past 5 years, Sarepta Therapeutics' median Income from Continuing Operations value was -$48.1 million (recorded in 2021), while the average stood at -$72.2 million.
  • In the last 5 years, Sarepta Therapeutics' Income from Continuing Operations tumbled by 85615.14% in 2021 and then soared by 294857.59% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Income from Continuing Operations stood at -$122.0 million in 2021, then rose by 9.94% to -$109.9 million in 2022, then soared by 141.44% to $45.5 million in 2023, then soared by 248.8% to $158.8 million in 2024, then increased by 24.02% to $196.9 million in 2025.
  • Its last three reported values are $196.9 million in Q2 2025, $158.8 million for Q4 2024, and $33.6 million during Q3 2024.